Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.

Blockhead10-16

Shares of Wave Life Sciences (WVE) surged to a four-year high Wednesday after the company announced "impressive" proof-of-concept results for its new technology in two patients with a genetic disease....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476945072?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/10/Stock-WaveLifeSciences-01-shutt-150x150.jpg","is_english":true,"pubTime":"2024-10-16 23:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476945072","market":"us","top_or_hot":-1,"title":"Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.","media":"Blockhead","content":"<div>\n<p>Shares of Wave Life Sciences (WVE) surged to a four-year high Wednesday after the company announced \"impressive\" proof-of-concept results for its new technology in two patients with a genetic disease....</p>\n\n<a href=\"https://www.investors.com/news/technology/wave-life-sciences-rna-editing-alpha-1-antitrypsin/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-16 23:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/wave-life-sciences-rna-editing-alpha-1-antitrypsin/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Wave Life Sciences (WVE) surged to a four-year high Wednesday after the company announced \"impressive\" proof-of-concept results for its new technology in two patients with a genetic disease....</p>\n\n<a href=\"https://www.investors.com/news/technology/wave-life-sciences-rna-editing-alpha-1-antitrypsin/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.investors.com/news/technology/wave-life-sciences-rna-editing-alpha-1-antitrypsin/","article_id":"2476945072","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/10/Stock-WaveLifeSciences-01-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476945072","pubTimestamp":1729093185,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Shares of Wave Life Sciences surged Wednesday after the company announced \"impressive\" proof-of-concept results for its new technology.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","WVE":"Wave Life Sciences Pte. Ltd","KRRO":"Korro Bio, Inc.","RNA":"Avidity Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Wave Life Sciences刚刚编辑了RNA。为什么它的主要竞争对手Korro Bio股价飙升。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":1,"RNA":1,"WVE":1},"content_text":"Shares of Wave Life Sciences (WVE) surged to a four-year high Wednesday after the company announced \"impressive\" proof-of-concept results for its new technology in two patients with a genetic disease.\nThe biotech company tested its experimental treatment in patients with alpha-1 antitrypsin deficiency. In this condition, the liver doesn't make enough — or any — of the AAT protein. This protein helps protect the lungs from damage. Without it, the lungs can become more easily damaged from smoking, pollution or dust.\nBut Wave's new means of editing RNA helped the patients generate a robust amount of the missing AAT protein 15 days after receiving a single dose. RNA is the messenger from DNA that carries the instructions for making proteins.\n\"This is the first clinical data point for RNA editing (from Wave Life Sciences or any others, as far as we know),\" Mizuho Securities analyst Salim Syed said in a report. \"And proof-of-concept for the platform.\"\nIn morning trades on today's stock market, Wave Life Sciences stock skyrocketed 73.9% to 14.88. Shares touched their highest point since September 2020, according to MarketSurge. The results also bolstered shares of Korro Bio (KRRO), which launched 131.2% to 91.94. William Blair analyst Myles Minter says Korro could have the best-in-class messenger RNA-editing platform.\n\n\n\n↑\nX\n\n\n\n\nThe Cell Therapy Market Is Expected To Grow 600% Over The Next Decade. This Biotech Is Poised To Capitalize On That Wave.\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nThe Cell Therapy Market Is Expected To Grow 600% Over The Next Decade. This Biotech Is Poised To Capitalize On That Wave.\n\n\n\n\nWave Life Sciences Plans Higher Doses\nIt's important to note, both patients are considered homozygous. This means they have two copies of the problematic gene attached to alpha-1 antitrypsin deficiency, or AATD.\n\"Therefore any production (of AAT protein) at all is proof-of-mechanism,\" Mizuho's Syed said.\nMore than 60% of the AAT protein in patients' plasma was wild-type — meaning unmutated. The threshold for clinical meaningfulness is 50%. This could be enough to lower the disease's risk, Syed said. Wave Life Sciences is also planning to test higher doses with results expected in 2025.\nHe has an outperform rating and 19 price target on Wave stock.\nLeerink Partners analyst Joseph Schwartz, who classified Wave's results as \"impressive,\" also noted Takeda Pharmaceutical opted out of another Wave Life Sciences program in a filing late Tuesday. Now, Wave is free to go alone or shop around for another partner for its Huntington's disease drug.\n\"When we caught up with management, they said it was simply a matter of strategy pipeline prioritization for Takeda, and Wave remains positive on the potential for an accelerated approval pathway,\" Schwartz said in a report.\nHe rates Wave Life Sciences stock an outperform.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nHims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug\nJ&J Stock Leapfrogs 50-Day Line After Health Care Titan Raises Sales Outlook\nWant To Get Quick Profits And Avoid Big Losses? Try SwingTrader\nStocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks\nLearn How To Time The Market With IBD's ETF Market Strategy","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476945072"}